Announcements Trials
Browse Landscape

Phase

Phase 3 1

Status

Active not recruiting 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

NET 1Gastrointestinal 1Endocrine 1

Conditions

Glioma 8Multiple Myeloma 7Sarcoma 6Rhabdoid Tumor 6Medulloblastoma 6Wilms Tumor 5Rhabdomyosarcoma 5Neuroectodermal Tumors, Primitive, Peripheral 5Neuroblastoma 5Lymphoma, Non-Hodgkin 5Lymphoma 5Histiocytosis, Langerhans-Cell 5Hepatoblastoma 5Ependymoma 5Central Nervous System Neoplasms 5Breast Neoplasms 5Prostatic Neoplasms 4Ovarian Neoplasms 4Osteosarcoma 4Pancreatic Neoplasms 3Lung Neoplasms 3Fallopian Tube Neoplasms 3Carcinoma, Hepatocellular 3Urinary Bladder Neoplasms 2Sarcoma, Ewing 2Rectal Neoplasms 2Precursor Cell Lymphoblastic Leukemia-Lymphoma 2Neuroendocrine Tumors 2Neoplasm Metastasis 2Malignant Solid Neoplasm 2

Interventions

Temozolomide 2Capecitabine 2lutetium Lu 177 dotatate 1cabozantinib 1atezolizumab 1abemaciclib 1X-Rays 1Specimen Handling 1Phantoms, Imaging 1Magnetic Resonance Spectroscopy 1Immunoglobulin G 1Disulfides 1Bevacizumab 111-(2-methylpropyl)-12,13-dihydro-2-methyl-8-(pyrimidin-2-ylamino)-4H-indazolo(5,4-a)pyrrolo(3,4-c)carbazol-4-one 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Active not recruiting × Adenoma, Islet Cell × X-Rays × Clear all
NCT03375320 2026-06-03

Testing Cabozantinib in Patients With Advanced Pancreatic Neuroendocrine and Carcinoid Tumors

National Cancer Institute (NCI)

Phase 3 Active not recruiting
298 enrolled 14 charts 1 FDA
EndocrineGastrointestinalNET

Non functioning pancreatic endocrine tumor, Adenoma, Islet Cell, Neuroendocrine Tumors

Data powered by HemOnc (CC BY 4.0) Colophon âš¡